Nancy L Bartlett,Laurie H Sehn,Sarit Assouline,Pratyush Giri,John Kuruvilla,Stephen J Schuster,Sung-Soo Yoon,Keith Fay,Georg Hess,Martin Dreyling,Norma C Gutierrez,Eva Cybulski,Fidelis Sabalvaro,Elicia Penuel,Vanda Teodoro,Samuel Tracy,Denison Kuruvilla,Joseph Chen,Volker Wiebking,Michael C Wei,L Elizabeth Budde
Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 prior therapies, alongside data from a within-study comparator cohort of mosunetuzumab IV in a similar patient population (N = 90; median follow-up: 22.5 months). The co-primary PK endpoints (Ctrough and AUC) were met, demonstrating non-inferior exposure of mosunetuzumab SC versus IV (observed Ctrough[C3]: geometric mean ratio [GMR] 1.39 [90% confidence interval (CI): 1.20-1.61]; AUC0-84: GMR 1.06 [90% CI: 0.92-1.21]). Mosunetuzumab SC efficacy was consistent with IV: overall response rate, 76.6% (95% CI: 66.7-84.7); complete response rate, 61.7% (95% CI: 51.1-71.5); median duration of complete response, 34.6 months (95% CI: 20.7-not evaluable [NE]); and median progression-free survival, 23.7 months (95% CI: 14.6-NE). Mosunetuzumab SC demonstrated a favorable safety profile versus mosunetuzumab IV with a numerically lower rate (29.8% vs. 44.4%) and severity (grade ≥ 2: 9.6% vs. 18.9%) of cytokine release syndrome (CRS) events. Mosunetuzumab SC combines the benefits of short administration time, fixed-duration treatment, outpatient accessibility, and low CRS rate, offering clinically meaningful improvements in patient convenience and safety. Trial Registration: www.clinicaltrials.gov: NCT02500407.
{"title":"Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.","authors":"Nancy L Bartlett,Laurie H Sehn,Sarit Assouline,Pratyush Giri,John Kuruvilla,Stephen J Schuster,Sung-Soo Yoon,Keith Fay,Georg Hess,Martin Dreyling,Norma C Gutierrez,Eva Cybulski,Fidelis Sabalvaro,Elicia Penuel,Vanda Teodoro,Samuel Tracy,Denison Kuruvilla,Joseph Chen,Volker Wiebking,Michael C Wei,L Elizabeth Budde","doi":"10.1002/ajh.70225","DOIUrl":"https://doi.org/10.1002/ajh.70225","url":null,"abstract":"Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 prior therapies, alongside data from a within-study comparator cohort of mosunetuzumab IV in a similar patient population (N = 90; median follow-up: 22.5 months). The co-primary PK endpoints (Ctrough and AUC) were met, demonstrating non-inferior exposure of mosunetuzumab SC versus IV (observed Ctrough[C3]: geometric mean ratio [GMR] 1.39 [90% confidence interval (CI): 1.20-1.61]; AUC0-84: GMR 1.06 [90% CI: 0.92-1.21]). Mosunetuzumab SC efficacy was consistent with IV: overall response rate, 76.6% (95% CI: 66.7-84.7); complete response rate, 61.7% (95% CI: 51.1-71.5); median duration of complete response, 34.6 months (95% CI: 20.7-not evaluable [NE]); and median progression-free survival, 23.7 months (95% CI: 14.6-NE). Mosunetuzumab SC demonstrated a favorable safety profile versus mosunetuzumab IV with a numerically lower rate (29.8% vs. 44.4%) and severity (grade ≥ 2: 9.6% vs. 18.9%) of cytokine release syndrome (CRS) events. Mosunetuzumab SC combines the benefits of short administration time, fixed-duration treatment, outpatient accessibility, and low CRS rate, offering clinically meaningful improvements in patient convenience and safety. Trial Registration: www.clinicaltrials.gov: NCT02500407.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"1 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147489961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthew J Rees,Raffaella Cassano Cassano,Melinda Tan,Eli Zolotov,Surbhi Sidana,Danai Dima,Jeries Kort,Aimaz Afrough,Mahmoud Gaballa,Oren Pasvolsky,Lekha Mikkilineni,Jack Khouri,Shahzad Raza,Saurabh S Zanwar,Christopher J Ferreri,Shaji Kumar,Adeel M Khan,Shebli Atrash,Andrew J Portuguese,Masooma Shifa Rana,Rahul Banerjee,Ciara Freeman,Brandon Blue,Krina K Patel,Larry D Anderson,Omar Castaneda Puglianini,Leyla O Shune,Noa Biran,Doris K Hansen,Yi Lin
{"title":"The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.","authors":"Matthew J Rees,Raffaella Cassano Cassano,Melinda Tan,Eli Zolotov,Surbhi Sidana,Danai Dima,Jeries Kort,Aimaz Afrough,Mahmoud Gaballa,Oren Pasvolsky,Lekha Mikkilineni,Jack Khouri,Shahzad Raza,Saurabh S Zanwar,Christopher J Ferreri,Shaji Kumar,Adeel M Khan,Shebli Atrash,Andrew J Portuguese,Masooma Shifa Rana,Rahul Banerjee,Ciara Freeman,Brandon Blue,Krina K Patel,Larry D Anderson,Omar Castaneda Puglianini,Leyla O Shune,Noa Biran,Doris K Hansen,Yi Lin","doi":"10.1002/ajh.70294","DOIUrl":"https://doi.org/10.1002/ajh.70294","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"28 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147489970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Joe Tuffnell, Jakob Passweg, Johannes Schetelig, Uwe Platzbecker, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Mareike Verbeek, Moniek A de Witte, Jean-Baptiste Méar, John A Snowden, Tobias A W Holderried, Gwendolyn van Gorkom, Frédéric Baron, Marie Robin, Xavier Poiré, Mieke W H Roeven, Maija Itälä-Remes, Jan Zaucha, Kavita Raj, Joanna Drozd-Sokolowska, Giorgia Battipaglia, Tomasz Czerw, Juan Carlos Hernández-Boluda, Nicola Polverelli, Donal P McLornan
{"title":"Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMT.","authors":"Yves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Joe Tuffnell, Jakob Passweg, Johannes Schetelig, Uwe Platzbecker, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Mareike Verbeek, Moniek A de Witte, Jean-Baptiste Méar, John A Snowden, Tobias A W Holderried, Gwendolyn van Gorkom, Frédéric Baron, Marie Robin, Xavier Poiré, Mieke W H Roeven, Maija Itälä-Remes, Jan Zaucha, Kavita Raj, Joanna Drozd-Sokolowska, Giorgia Battipaglia, Tomasz Czerw, Juan Carlos Hernández-Boluda, Nicola Polverelli, Donal P McLornan","doi":"10.1002/ajh.70288","DOIUrl":"https://doi.org/10.1002/ajh.70288","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lukas H Haaksma,Tom Reuvekamp,Kasper J Croese,Maximiliaan Muijtjens,Angéle Kelder,Daphne den Hartog,Willemijn J Scholten,Thomas Pabst,Saskia K Klein,Georg Stüssi,Laimonas Griskevicius,Dimitri A Breems,Lidwine Tick,Alexandra Herbers,Susan de Jonge,Dana A Chitu,Costa Bachas,Gerwin Huls,Jacqueline Cloos,David C de Leeuw
{"title":"Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.","authors":"Lukas H Haaksma,Tom Reuvekamp,Kasper J Croese,Maximiliaan Muijtjens,Angéle Kelder,Daphne den Hartog,Willemijn J Scholten,Thomas Pabst,Saskia K Klein,Georg Stüssi,Laimonas Griskevicius,Dimitri A Breems,Lidwine Tick,Alexandra Herbers,Susan de Jonge,Dana A Chitu,Costa Bachas,Gerwin Huls,Jacqueline Cloos,David C de Leeuw","doi":"10.1002/ajh.70291","DOIUrl":"https://doi.org/10.1002/ajh.70291","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"8 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marion Serra, Steven Akkaya, Marine Aglave, Mohammad Salma, Sara Bencheikh, Patricia Hermand, Carine Lefevre, Romain Duval, Jade Merrer, Fallou Leye, Joelle Magne, Isabelle Plo, Lionel Blanc, Eric Soler, Slim Azouzi, Berengere Koehl
Neutrophils and monocytes are persistently elevated in sickle cell anemia (SCA), yet the intrinsic mechanisms driving pathological myelopoiesis and inflammation remain poorly defined. Through single‐cell RNA sequencing and functional assays, we demonstrate that hematopoietic stem and multipotent progenitor cells (HSPCs) in SCA are transcriptionally reprogrammed toward myeloid differentiation. This process is orchestrated by aberrant activation of Type I interferon (IFN‐I) signaling, which promotes premature myeloid commitment of hematopoietic stem cells. SCA progenitors further exhibit unexpected responsiveness to granulocyte colony‐stimulating factor (G‐CSF) through upregulation of CSF3R, resulting in skewed myelopoiesis toward the monocytic lineage. Importantly, hydroxyurea treatment attenuates IFN‐I signaling in neutrophils, consistent with its therapeutic role in reducing excessive inflammation and granulopoiesis. Collectively, these findings uncover IFN‐I–driven remodeling of hematopoiesis as a fundamental mechanism of leukocytosis and chronic inflammation in SCA, and establish a tractable therapeutic axis to mitigate innate immunity activation in this disease.
{"title":"IFN ‐ I ‐Mediated Transcriptional Reprogramming Drives Myeloid‐Skewed Hematopoiesis in Sickle Cell Anemia","authors":"Marion Serra, Steven Akkaya, Marine Aglave, Mohammad Salma, Sara Bencheikh, Patricia Hermand, Carine Lefevre, Romain Duval, Jade Merrer, Fallou Leye, Joelle Magne, Isabelle Plo, Lionel Blanc, Eric Soler, Slim Azouzi, Berengere Koehl","doi":"10.1002/ajh.70277","DOIUrl":"https://doi.org/10.1002/ajh.70277","url":null,"abstract":"Neutrophils and monocytes are persistently elevated in sickle cell anemia (SCA), yet the intrinsic mechanisms driving pathological myelopoiesis and inflammation remain poorly defined. Through single‐cell RNA sequencing and functional assays, we demonstrate that hematopoietic stem and multipotent progenitor cells (HSPCs) in SCA are transcriptionally reprogrammed toward myeloid differentiation. This process is orchestrated by aberrant activation of Type I interferon (IFN‐I) signaling, which promotes premature myeloid commitment of hematopoietic stem cells. SCA progenitors further exhibit unexpected responsiveness to granulocyte colony‐stimulating factor (G‐CSF) through upregulation of CSF3R, resulting in skewed myelopoiesis toward the monocytic lineage. Importantly, hydroxyurea treatment attenuates IFN‐I signaling in neutrophils, consistent with its therapeutic role in reducing excessive inflammation and granulopoiesis. Collectively, these findings uncover IFN‐I–driven remodeling of hematopoiesis as a fundamental mechanism of leukocytosis and chronic inflammation in SCA, and establish a tractable therapeutic axis to mitigate innate immunity activation in this disease.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"12 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147478119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Geoffrey Shouse, Matthew Matasar, Lu Chen, Jennifer Crombie, Jonathon Cohen, Ranjana Advani, Ann LaCasce, Leslie Popplewell, Sandrine Puverel, Lacolle Peters, Shari Daniels, James Godfrey, Matthew Mei, Swetha Thiruvengadam, Lihua E. Budde, Liana Nikolaenko, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Alex F. Herrera
Salvage chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) remains a standard therapy for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL) who relapse > 1 year after frontline treatment. We evaluated the safety and efficacy of polatuzumab vedotin (Pola) combined with R‐ICE salvage chemotherapy, followed by post‐ASCT Pola maintenance, aiming to improve complete response (CR) rates and enhance post‐ASCT outcomes in r/r DLBCL. Notably, the study's accrual period predated the approvals of second‐line CAR T cell therapies. Forty‐one patients were enrolled and received PolaR‐ICE. Adverse effects of the combination were consistent with those observed with Pola and R‐ICE chemotherapy with no new toxicity signals observed and were most commonly hematologic and gastrointestinal. The overall response rate after salvage was 88% with a CR rate of 56%. Twenty‐two patients (56%) went on to receive autologous stem cell transplant and 16 (39%) received Pola consolidation. At a median follow‐up of 25 months (range: 18–21), the 2‐year PFS of all patients treated with PolaR‐ICE ( n = 41) was 49.9% (95% CI: 31.7–65.7) and 2‐year OS was 75.0% (95% CI: 58.5–85.8). Patients with relapse ≤ 12 months of initial therapy achieved a 2‐year PFS of 36.4% (90% CI: 17.1–56.0) versus 80.0% (95% CI: 40.9–94.6) among patients with relapse ≥ 12 months. Our findings demonstrate that Pola‐RICE is a safe and effective salvage regimen for r/r DLBCL, which can be considered for patients with late relapse or in areas where CAR T access may be limited. Trial Registration: ClinicalTrials.gov identifier: NCT04665765
{"title":"Polatuzumab Vedotin Combined With R ‐ ICE ( PolaR ‐ ICE ) as Second‐Line Therapy in Diffuse Large B ‐Cell Lymphoma","authors":"Geoffrey Shouse, Matthew Matasar, Lu Chen, Jennifer Crombie, Jonathon Cohen, Ranjana Advani, Ann LaCasce, Leslie Popplewell, Sandrine Puverel, Lacolle Peters, Shari Daniels, James Godfrey, Matthew Mei, Swetha Thiruvengadam, Lihua E. Budde, Liana Nikolaenko, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Alex F. Herrera","doi":"10.1002/ajh.70282","DOIUrl":"https://doi.org/10.1002/ajh.70282","url":null,"abstract":"Salvage chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) remains a standard therapy for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL) who relapse > 1 year after frontline treatment. We evaluated the safety and efficacy of polatuzumab vedotin (Pola) combined with R‐ICE salvage chemotherapy, followed by post‐ASCT Pola maintenance, aiming to improve complete response (CR) rates and enhance post‐ASCT outcomes in r/r DLBCL. Notably, the study's accrual period predated the approvals of second‐line CAR T cell therapies. Forty‐one patients were enrolled and received PolaR‐ICE. Adverse effects of the combination were consistent with those observed with Pola and R‐ICE chemotherapy with no new toxicity signals observed and were most commonly hematologic and gastrointestinal. The overall response rate after salvage was 88% with a CR rate of 56%. Twenty‐two patients (56%) went on to receive autologous stem cell transplant and 16 (39%) received Pola consolidation. At a median follow‐up of 25 months (range: 18–21), the 2‐year PFS of all patients treated with PolaR‐ICE ( <jats:italic>n</jats:italic> = 41) was 49.9% (95% CI: 31.7–65.7) and 2‐year OS was 75.0% (95% CI: 58.5–85.8). Patients with relapse ≤ 12 months of initial therapy achieved a 2‐year PFS of 36.4% (90% CI: 17.1–56.0) versus 80.0% (95% CI: 40.9–94.6) among patients with relapse ≥ 12 months. Our findings demonstrate that Pola‐RICE is a safe and effective salvage regimen for r/r DLBCL, which can be considered for patients with late relapse or in areas where CAR T access may be limited. Trial Registration: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link> identifier: NCT04665765","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"13 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Florian Chevillon,Laure Goursaud,Paul Chauvet,Laurent Quero,Alban Villate,Matthieu Jestin,Nathalie Dhédin,Éléonore Kaphan,Régis Peffault De Latour,Laurène Fenwarth,Benoit Catteau,Nicole Raus,Maud D'Aveni,Alain Sarasin,Flore Sicre de Fontbrune
{"title":"Feasibility of Allogeneic Stem Cell Transplantation in Xeroderma Pigmentosum Patients With Hematologic Malignancies, a Report From the SFGM-TC (Société Francophone de Greffe de Moelle et de Thérapie Cellulaire).","authors":"Florian Chevillon,Laure Goursaud,Paul Chauvet,Laurent Quero,Alban Villate,Matthieu Jestin,Nathalie Dhédin,Éléonore Kaphan,Régis Peffault De Latour,Laurène Fenwarth,Benoit Catteau,Nicole Raus,Maud D'Aveni,Alain Sarasin,Flore Sicre de Fontbrune","doi":"10.1002/ajh.70273","DOIUrl":"https://doi.org/10.1002/ajh.70273","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"86 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wouter Verhaar,Flores Weverling,Jahanzaib Khwaja,Despina Trajanova,Martine Chamuleau,Kirsty Cuthill,Shirley D'Sa,Paul A F Geerts,Kaz Groen,Troels Hammer,Marie José Kersten,Ida B Kristensen,Suzanne Lentzsch,Sophie Bernelot Moens,Amy Song,Andre J Vlot,Peter E Westerweel,Ute Hegenbart,Stefan Schönland,Ashutosh Wechalekar,Monique C Minnema,Josephine M I Vos
{"title":"Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.","authors":"Wouter Verhaar,Flores Weverling,Jahanzaib Khwaja,Despina Trajanova,Martine Chamuleau,Kirsty Cuthill,Shirley D'Sa,Paul A F Geerts,Kaz Groen,Troels Hammer,Marie José Kersten,Ida B Kristensen,Suzanne Lentzsch,Sophie Bernelot Moens,Amy Song,Andre J Vlot,Peter E Westerweel,Ute Hegenbart,Stefan Schönland,Ashutosh Wechalekar,Monique C Minnema,Josephine M I Vos","doi":"10.1002/ajh.70267","DOIUrl":"https://doi.org/10.1002/ajh.70267","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"218 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：